Abstract
Pegylated liposomal doxorubicin (PLD) is a drug whose use is increasingly common. It has been associated with a lower rate of haematologic and cardiac side effects than its nonencapsulated form. However, mucocutaneous toxicity is quite frequent and can be severe. Here we provide a case report of a patient who developed an intertrigolike eruption during treatment with PLD.
Similar content being viewed by others
References
Aimee SP, William DJ, Raymond BW (2006) Dermatologic toxicity of chemotherapeutic agents. Semin Oncol 33:86–97
Lotem M, Hubert A, Lyass O et al (2000) Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 136:1475–1480
Lyass O, Uziely B, Ben-Yosef R et al (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 89:1037–1047
English JC 3rd, Toney R, Patterson JW (2003) Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin. J Cutan Pathol 30:591–595
Korac B, Buzadzic B (2001) Doxorubicin toxicity to the skin: possibility of protection with antioxidants enriched yeast. J Dermatol Sci 25:45–52
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sánchez Henarejos, P., Ros Martínez, S., Marín Zafra, G.R. et al. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD). Clin Transl Oncol 11, 486–487 (2009). https://doi.org/10.1007/s12094-009-0390-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-009-0390-2